The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia.
Intravesical oxybutynin chloride was administered to 11 children and 7 adults with upper motor neuron bladder dysfunction who were refractory to oral use or who had intolerable side effects from the medication. This therapy was combined with clean intermittent catheterization to ensure complete emptying of the bladder. Five children and 5 adults discontinued therapy due to side effects or the inconvenience of the procedure. The remaining 6 children and 2 adults continue the medication successfully and have shown on followup urodynamic studies that bladder volumes are greater and intravesical pressures are lower than before medication. Intravesical oxybutynin chloride seems to be an effective modality to treat some of these patients but it is not without significant side effects.
Kasabian
N G
NG
Department of Surgery, Children's Hospital, Boston, Massachusetts.
Vlachiotis
J D
JD
Lais
A
A
Klumpp
B
B
Kelly
M D
MD
Siroky
M B
MB
Bauer
S B
SB
D000283:Administration, Intravesical; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D006801:Humans; D008333:Mandelic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D009130:Muscle, Smooth / Q000294:innervation / Q000503:physiopathology; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D012021:Reflex, Abnormal; D001743:Urinary Bladder / Q000294:innervation / Q000503:physiopathology; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014563:Urodynamics
D008333:Mandelic Acids; D010276:Parasympatholytics; C005419:oxybutynin